Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications
Author:
Funder
Pfizer
Novartis
Roche
Publisher
Elsevier BV
Subject
Radiology Nuclear Medicine and imaging,Oncology,General Medicine
Reference63 articles.
1. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review;Gupta;Cancer Treat Rev,2008
2. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma;Kapoor;Cancer,2009
3. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol;Antonelli;BJU Int,2007
4. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007
5. For the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Treating primary lymphoma of the brain in AIDS patients via multifunctional oral nanoparticulate systems;Nanomedicine;2022-03
2. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors;American Journal of Clinical Oncology;2021-07-26
3. Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL;Cancers;2021-03-13
4. Clinical analysis of everolimus in the treatment of metastatic renal cell carcinoma;Annals of Palliative Medicine;2021-01
5. Nanotoxicology of an Elastin-like Polypeptide Rapamycin Formulation for Breast Cancer;Biomacromolecules;2020-01-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3